Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926990 · ClinicalTrials.gov registry record
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 19
- Enrollment target
NCT01926990: Completed study, sponsored by Stanford University.
NCT01926990 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01926990 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Interventions
- DEVICE perfusion computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-08 |
| Est. Completion | 2021-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01926990
The ClinicalTrials.gov registry entry for NCT01926990 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which perfusion computed tomography is the first listed.
NCT01926990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01926990 about?
NCT01926990 is a clinical study titled "Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma". This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and ...
What is the current status of trial NCT01926990?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2014-08. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT01926990?
The interventions under investigation include: perfusion computed tomography (DEVICE).
Who is sponsoring clinical trial NCT01926990?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.